Protocol Ledger

NCT05397470 · Phase III · TERMINATED

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Interventional Phase III clinical trial protocol NCT05397470 sponsored by Fulcrum Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-16 Enrollment: 260 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05397470
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)260 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05397470
Protocol FieldVerified Registry Value
NCT IdentifierNCT05397470
Consolidated Lead SponsorFulcrum Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment260 participants (ACTUAL)
Registered Start Date2022-06-16
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI